
Table of Contents

Foreword	xix
Preface	xxi
About the Editors	xxiii

Blood Products and Derivatives

1. Blood Components: Preparation and Modification	1
<i>N. Rebecca Haley, MD; Matthew Hiskey, MD; Russ Juntunen; and Hamilton Tsang, MD</i>	
Blood Collection	1
Whole Blood: Past and Current Preparations	5
Red Blood Cells	7
Plasma	8
Platelets	12
Cryoprecipitate	17
Granulocytes	18
Blood Component Modifications	19
Labeling	22
Summary	23
References	23
2. Red Cell Transfusion Therapy in Anemia	29
<i>Carolyn D. Burns, MD; Zhan Ye, MD, PhD; Phillip J. DeChristopher, MD, PhD; and Jay E. Menitove, MD</i>	
Introduction	31
Oxygen Transport Physiology	31
Physiologic Compensatory Factors Affecting Oxygen Delivery	33
Critical Hemoglobin Concentration	35

Clinical and Experimental Observations in Anemia	36
Nontransfusion Alternatives	46
Additional Considerations	47
Summary	53
References	54
3. Platelet Transfusion Therapy	67
<i>Tina S. Ipe, MD, MPH, and Deborah Sesok-Pizzini, MD, MBA</i>	
Platelet Products	68
Platelet Refractoriness: Etiology, Prevention, and Management	73
Indications for Platelet Transfusion	75
Assessment and Dose	87
Selected Adverse Events: Bacterial Contamination and Alloimmunization	93
Platelet Additive Solutions	94
Red Cell Transfusion for Thrombocytopenic and Thrombocytopathic Bleeding	96
Summary	97
References	97
4. Plasma Therapy: Available Components, Indications, Dosing, and Special Circumstances	109
<i>Christopher A. Tormey, MD, and Sara Rutter, MD</i>	
Plasma Products Routinely Available for Use in the United States	110
Dosing Considerations When Planning Plasma Therapy	115
Issuing and Administration Issues Surrounding Plasma Infusion	120
Clinical Scenarios for which Plasma Transfusion May Be Considered	122
Special Considerations for Plasma Infusion	128
Alternatives to Plasma in Select Situations	129
Summary	131
References	132
5. Cryoprecipitate: Indications and Dosing	139
<i>Jason E. Crane, DO, and Mona Papari, MD</i>	
Manufacturing	140
Indications	140
Adverse Reactions	143
Dosing	144
Alternatives to Cryoprecipitate	144
Summary	145
References	145

6. Granulocyte Transfusion	149
<i>Yvette C. Tanhehco, PhD, MD, MS</i>	
Rationale	149
Granulocyte Collection	149
Granulocyte Transfusion	152
Standards and Regulatory Requirements	152
Clinical Outcomes	153
Summary	154
References	155
7. Blood Derivatives and Growth Factors	159
<i>Amy E. Schmidt, MD, PhD, and Majed A. Refaai, MD</i>	
Immunoglobulin Therapy	160
Rh Immune Globulin Therapy	163
Albumin	167
Plasma-Derived Clotting Factors	169
Antithrombin	172
Factor XIII	173
Protein C	173
Fibrinogen Concentrates	174
Prothrombin Complex Concentrates	175
Other Plasma-Derived Proteins	176
Fibrin Sealants	177
Hematopoietic Growth Factors	179
Summary	184
References	184
8. Platelet-Rich Plasma	195
<i>Claudia S. Cohn, MD, PhD</i>	
Platelet Physiology and Wound Healing	196
PRP Production and Administration	196
How Does PRP Work?	205
Does PRP Work? Meta-Data	205
PRP Use in Orthopedic Surgery: A Closer Look at Some RCT Data	207
Summary	214
References	214

Transfusion Medicine Practice

9. Transfusion Reactions and Adverse Events of Transfusion 219
Radhika Gangaraju, MD, and Marisa B. Marques, MD
Acute or Immediate Transfusion Reactions 220
Delayed Transfusion Reactions 235
Summary 238
References 239

10. Transfusion Therapy in Autoimmune Hemolytic Anemia 245
Anne F. Eder, MD, PhD
Warm Autoimmune Hemolytic Anemia 247
Cold Agglutinins and Cold Agglutinin Disease 258
Autoimmune Hemolytic Anemia with Both Warm and Cold Autoantibodies 266
Paroxysmal Cold Hemoglobinuria 266
Drug-Induced Immune Hemolytic Anemia 269
Summary 274
References 274

11. Pregnancy and Postpartum Transfusion Considerations 279
Bryan Guillory, MD, and James Sikora, MD
Pregnant Patients as Transfusion Recipients 279
Antepartum Hemorrhage 280
Postpartum Hemorrhage 281
Genetic Hemostatic Disorders 283
Blood Component Selection for Obstetric Hemorrhage 285
Transfusion Thresholds for Patients with Obstetric Hemorrhage 285
Transfusion Considerations in Pregnant Patients with Sickle Cell Disease 286
Summary 287
References 287

12. Intrauterine, Neonatal, and Pediatric Transfusion Therapy 291
*Nabiba H. Saifee, MD, PhD; Wendy Lau, MBBS, FRCPC; and
Amy Keir, MBBS, MPH, PhD*
Fetuses as Transfusion Recipients 291
Neonates as Transfusion Recipients 305
Transfusion Beyond the Neonatal Period 318
Summary 331
References 331

13. Transfusion Therapy in Hematopoietic Stem Cell Transplantation	343
<i>Matthew C. Canver, MD, PhD, and Melissa M. Cushing, MD</i>	
The Effect of ABO Incompatibility on HSCT Clinical Outcomes	344
Blood Component Transfusion Support in HSCT Patients	345
Considerations for Transfusion Support of Pediatric HSCT Patients	349
Special Processing for Transfusion Support in HSCT Patients	350
Summary	351
References	351
14. Transfusion Practice in Solid Organ Transplantation	359
<i>Brie A. Stotler, MD, MPH, and Sarah R. Vossoughi, MD</i>	
Best-Accepted Practices	360
Transfusion Support	362
Areas of Interest	363
Immuno-hematologic Considerations	365
Allograft Donor Infectious Disease Testing	367
Summary	368
References	368
15. Transfusion Support and Hemostatic Monitoring in Patients Connected to Extracorporeal Devices	375
<i>Huy P. Pham, MD, MPH; Elizabeth M. Staley, MD, PhD; and Edward C.C. Wong, MD</i>	
Clinical Indications and Evidence for Using ECLS	376
Complications of ECLS	379
Anticoagulation Protocols	381
Anticoagulation Monitoring	383
Transfusion Requirements	384
Summary	388
References	388
16. Transfusion-Related Considerations in Jehovah's Witness Patients	395
<i>Robert A. DeSimone, MD</i>	
Overview	395
Mortality When Transfusion Is Not an Option	396
Prohibited Products and Procedures	396
Permitted Products and Procedures	397
Management of Critical Anemia	397
Perioperative Considerations	398
Pediatric Considerations	400
Summary	400
References	400

17. Principles of Hemostasis and Laboratory Testing 403

Geoffrey Wool, MD, PhD, and Cyril Jacquot, MD, PhD

Principles of Primary Hemostasis and Laboratory Testing 404
Primary Hemostasis Laboratory Testing 408
Principles of Secondary Hemostasis and Laboratory Testing 418
Secondary Hemostasis Laboratory Testing 425
Principles and Laboratory Testing of Clot Crosslinking and Fibrinolysis 430
Clot Crosslinking and Fibrinolysis Laboratory Testing 433
Viscoelastic Analysis 434
Activated Clotting Time 441
Summary 441
References 442

18. Pathophysiology and Management of Hemostatic Disorders 451

Cyril Jacquot, MD, PhD, and Geoffrey Wool, MD, PhD

Congenital Primary Hemostasis Disorders 452
Acquired Primary Hemostasis Disorders 457
Congenital Secondary Hemostasis Disorders 460
Acquired Secondary Hemostasis Disorders 470
Acquired Coagulation Inhibitors: Acquired Hemophilia A—Factor VIII
Autoantibodies 475
Hyperfibrinolysis Disorders 476
Anticoagulation and Laboratory Monitoring 477
Summary 484
Acknowledgment 484
References 484

Management Aspects of Transfusion Practice

19. Patient Blood Management 497

Steven M. Frank, MD; Brian C. Cho, MD; and Eric A. Gebrie, MD

What Is Patient Blood Management? 498
Support for a PBM Program 498
Standards and Certification for Patient Blood Management 499
Methods of Patient Blood Management 499
Patient Blood Management Data 518
Transfusion Extremes 519
Summary 523
Acknowledgment 523
References 523

20. Hemovigilance	529
<i>James R. Stubbs, MD; Aleh Bobr, MD; Margaret A. DiGuardo, MD; and Nancy Van Buren, MD</i>	
Hemovigilance Overview	530
Hemovigilance System Components	530
Hemovigilance Outside of the United States	532
Hemovigilance in the United States	533
Summary	536
Acknowledgment	536
References	536
21. Medical-Legal Issues in Transfusion Medicine	539
<i>J. Mills Barbeau, MD, JD</i>	
Fundamental Legal Concepts	539
The Law of Negligence	540
Informed Consent	544
Strict Liability	545
Medical Malpractice Statutes	546
Summary	547
References	547
22. Quality and Regulation in Transfusion Medicine	551
<i>Emily K. Storch, MD</i>	
Overview	551
Quality Assessment of Transfusion Practice	553
The Transfusion Committee	556
Regulation and Accreditation Requirements for Blood Banks and Transfusion Services	569
Summary	573
References	574
Index	581